Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3690945

CCCCCCCCCCOc1ccc(C(=O)NC(CC(=O)O)C[N+](C)(C)C)cc1.O=C([O-])C(F)(F)F

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.52
PPARA Q07869 1/20 0.52
CPT2 P23786 1/20 0.49
CPT1A P50416 1/20 0.49
CPT1B Q92523 1/20 0.49
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
PLA2G4B P0C869 1/20 0.45
S1PR1 P21453 1/20 0.44
S1PR3 Q99500 1/20 0.44
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43
RARB P10826 3/20 0.43
PLK1 P53350 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3690941 1.00 PPARG (0.52) PPARGPPARACPT2CPT1ACPT1B
Trifluoroacetic Acid SCHEMBL3690939 0.94 PPARG (0.53) PPARGPPARACPT2CPT1ACPT1B
SCHEMBL13409973 0.92 PPARG (0.60) PPARGPPARACPT2CPT1ACPT1B
SCHEMBL3690943 0.85 PPARG (0.49) PPARGPPARACPT2CPT1ACPT1B
SCHEMBL13409926 0.84 PLK1 (0.53) PPARGPPARATSHRPLK1
SCHEMBL14823000 0.81 PPARG (0.65) PPARGPPARATP53TSHRPLA2G4B
SCHEMBL3682901 0.79 CPT2 (0.53) PPARGPPARACPT2CPT1ACPT1B
SCHEMBL3682905 0.79 CPT2 (0.53) PPARGPPARACPT2CPT1ACPT1B
Trifluoroacetic Acid SCHEMBL3679509 0.79 MMP2 (0.43) MMP9
Trifluoroacetic Acid SCHEMBL3679514 0.79 MMP2 (0.43) MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008109991-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2008-09-18 WO claimed
US-8410150-B2 Inhibitors of carnitine palmitoyltransferase and treating cancer UNIVERSITY HEALTH NETWORK (CA) 2013-04-02 US disclosed
US-20100105900-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK 2010-04-29 US disclosed
WO-2008109991-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105900-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER CPT1A, CPT1B, CPT2 PPARG 488/4885PPARA 199/4885CPT2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.